In a retrospective study using patient tissues from the CORE and CENTRIC trials, which tested the efficacy of cilengitide in glioblastoma, the expression of target integrins was associated with clinical response to cilengitide: improved progression-free survival was reported in glioblastoma patients whose tumors expressed ITGAV:ITGB3 [38]. The gene discussed is ITGAV; the disease is glioblastoma.